174 related articles for article (PubMed ID: 33509437)
1. Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells.
Jha BK; Saunthararajah Y
Semin Hematol; 2021 Jan; 58(1):1-3. PubMed ID: 33509437
[TBL] [Abstract][Full Text] [Related]
2. Ultimate Precision: Targeting Cancer but Not Normal Self-replication.
Velcheti V; Schrump D; Saunthararajah Y
Am Soc Clin Oncol Educ Book; 2018 May; 38():950-963. PubMed ID: 30231326
[TBL] [Abstract][Full Text] [Related]
3. Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.
Gu X; Hu Z; Ebrahem Q; Crabb JS; Mahfouz RZ; Radivoyevitch T; Crabb JW; Saunthararajah Y
J Biol Chem; 2014 May; 289(21):14881-95. PubMed ID: 24695740
[TBL] [Abstract][Full Text] [Related]
4. Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer.
Velcheti V; Radivoyevitch T; Saunthararajah Y
Am Soc Clin Oncol Educ Book; 2017; 37():812-824. PubMed ID: 28561650
[TBL] [Abstract][Full Text] [Related]
5. PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation.
Gu X; Enane F; Tohme R; Schuerger C; Radivoyevitch T; Parker Y; Zuberi E; Przychodzen B; Jha BK; Lindner D; Rini B; Saunthararajah Y
Cell Rep; 2021 Sep; 36(12):109747. PubMed ID: 34551289
[TBL] [Abstract][Full Text] [Related]
6. Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells.
Enane FO; Saunthararajah Y; Korc M
Cell Death Dis; 2018 Sep; 9(9):912. PubMed ID: 30190481
[TBL] [Abstract][Full Text] [Related]
7. Equilibrium interactions of corepressors and coactivators with agonist and antagonist complexes of glucocorticoid receptors.
Wang Q; Blackford JA; Song LN; Huang Y; Cho S; Simons SS
Mol Endocrinol; 2004 Jun; 18(6):1376-95. PubMed ID: 15016838
[TBL] [Abstract][Full Text] [Related]
8. Thyroid hormone receptor coactivators and corepressors.
Koenig RJ
Thyroid; 1998 Aug; 8(8):703-13. PubMed ID: 9737367
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic control of ovarian function: the emerging role of histone modifications.
LaVoie HA
Mol Cell Endocrinol; 2005 Nov; 243(1-2):12-8. PubMed ID: 16219412
[TBL] [Abstract][Full Text] [Related]
10. Coactivators and corepressors of NF-kappaB in IkappaB alpha gene promoter.
Gao Z; Chiao P; Zhang X; Zhang X; Lazar MA; Seto E; Young HA; Ye J
J Biol Chem; 2005 Jun; 280(22):21091-8. PubMed ID: 15811852
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic modifying enzyme expression in asthmatic airway epithelial cells and fibroblasts.
Stefanowicz D; Ullah J; Lee K; Shaheen F; Olumese E; Fishbane N; Koo HK; Hallstrand TS; Knight DA; Hackett TL
BMC Pulm Med; 2017 Jan; 17(1):24. PubMed ID: 28137284
[TBL] [Abstract][Full Text] [Related]
12. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
Yoon HG; Wong J
Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic activities in erythroid cell gene regulation.
Wang Y; Yu L; Engel JD; Singh SA
Semin Hematol; 2021 Jan; 58(1):4-9. PubMed ID: 33509442
[TBL] [Abstract][Full Text] [Related]
14. Repression of bone morphogenetic protein and activin-inducible transcription by Evi-1.
Alliston T; Ko TC; Cao Y; Liang YY; Feng XH; Chang C; Derynck R
J Biol Chem; 2005 Jun; 280(25):24227-37. PubMed ID: 15849193
[TBL] [Abstract][Full Text] [Related]
15. Targeting transcription factor corepressors in tumor cells.
Vaiopoulos AG; Kostakis ID; Athanasoula KCh; Papavassiliou AG
Cell Mol Life Sci; 2012 Jun; 69(11):1745-53. PubMed ID: 22527719
[TBL] [Abstract][Full Text] [Related]
16. Coactivators and corepressors as mediators of nuclear receptor function: an update.
Jenster G
Mol Cell Endocrinol; 1998 Aug; 143(1-2):1-7. PubMed ID: 9806345
[TBL] [Abstract][Full Text] [Related]
17. Thyroid hormone response element architecture affects corepressor release from thyroid hormone receptor dimers.
Olson DP; Sun B; Koenig RJ
J Biol Chem; 1998 Feb; 273(6):3375-80. PubMed ID: 9452457
[TBL] [Abstract][Full Text] [Related]
18. Corepressors of agonist-bound nuclear receptors.
Gurevich I; Flores AM; Aneskievich BJ
Toxicol Appl Pharmacol; 2007 Sep; 223(3):288-98. PubMed ID: 17628626
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor corepressors: an overview.
Wang L; Hsu CL; Chang C
Prostate; 2005 May; 63(2):117-30. PubMed ID: 15486994
[TBL] [Abstract][Full Text] [Related]
20. Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic β-type globin promoters in differentiated adult erythroid cells.
Cui S; Kolodziej KE; Obara N; Amaral-Psarris A; Demmers J; Shi L; Engel JD; Grosveld F; Strouboulis J; Tanabe O
Mol Cell Biol; 2011 Aug; 31(16):3298-311. PubMed ID: 21670149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
